Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Document › Details

Exscientia Ltd.. (1/4/21). "Press Release: Exscientia Launches Miami Office to Recruit US-based Technology Talent as Part of Continued Expansion".

Organisations Organisation Exscientia Ltd. (ex scientia)
  Group Exscientia (Group)
  Organisation 2 Exscientia, Miami Office
  Group Exscientia (Group)
Products Product AI-based drug discovery
  Product 2 Centaur Biologist® AI-based drug discovery platform
Persons Person Hopkins, Andrew (Ex Scientia 201604 CEO)
  Person 2 Crisp, Stephanie (Edelman 202103)
     


Exscientia, the world-leading artificial intelligence (AI) driven Pharmatech company, today announces the opening of its US based Miami office, with recruitment starting immediately.

Led by Chief Research Engineer, Adrian Schreyer, Exscientia are recruiting both AI Engineers and Cheminformaticians to join the new Miami office. Members of the team will have extensive opportunities to work in the globally important field of AI-driven drug design and be part of an interdisciplinary team of talented researchers based across the UK, US and Japan.

Current opportunities are on the Exscientia careers page (sub-headed Miami FL) https://www.exscientia.ai/careers and will be actively updated as further openings become available.

Commenting on the announcement, Andrew Hopkins, Exscientia's CEO said, "We're looking for talented individuals and are particularly interested to tap in to Miami's true potential as a leading technology hub. We believe Miami is an excellent location and a future leader in the AI space"


About Exscientia??

Exscientia is a global leading Pharmatech company, using Artificial Intelligence (AI) to drive?drug discovery and is the first AI company to have designed a novel molecule to enter the clinic. Founded in 2012, Exscientia fuses the power of AI with the experience of seasoned drug hunters.?Exscientia’s innovative Centaur Chemist® platform enables breakthrough productivity gains as well as new approaches to improve drug design. Novel compounds are automatically designed and prioritized for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.?

Exscientia’s?Centaur?Biologist® platform drives the flexible analysis and prioritisation of discovery targets across all pharmaceutically relevant disease space. Exscientia is collaborating with several leading pharmaceutical and life sciences companies as well as building its own portfolio of innovative medicines. Exscientia has its headquarters in Oxford, England with further offices in?Dundee,?Scotland,?the?USA?and Japan. For more information visit us on?www.exscientia.ai?or follow us on Twitter?@exscientiaAI


Enquiries:

Edelman PR:
Anitra Sprauten; Edelman UK
P: +44 (0)78 9685 9386
Anitra.Sprauten@edelman.com

Stephanie Crisp; Edelman UK
P: +44 (0)75 8300 3417
stephanie.crisp@edelman.com

Exscientia:

Mark Swindells; Chief Commercial Officer
contact@exscientia.ai

   
Record changed: 2021-04-21

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Exscientia (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top